TC-1698
Topic: Chemistry
From HandWiki - Reading time: 6 min
Short description: Chemical compound
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C13H18N2 |
| Molar mass | 202.301 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
TC-1698 is a drug developed by Targacept which acts as a partial agonist for the α7 subtype of neural nicotinic acetylcholine receptors.[1] It has neuroprotective effects in animal studies,[2] and has been used as a lead compound to find further potent derivatives.[3]
See also
References
- ↑ "Central nicotinic receptors: structure, function, ligands, and therapeutic potential". ChemMedChem 2 (6): 746–67. June 2007. doi:10.1002/cmdc.200600207. PMID 17295372.
- ↑ "The neuroprotective effect of 2-(3-pyridyl)-1-azabicyclo[3.2.2]nonane (TC-1698), a novel alpha7 ligand, is prevented through angiotensin II activation of a tyrosine phosphatase". The Journal of Pharmacology and Experimental Therapeutics 309 (1): 16–27. April 2004. doi:10.1124/jpet.103.061655. PMID 14722323.
- ↑ "Synthesis of 2-(pyridin-3-yl)-1-azabicyclo[3.2.2]nonane, 2-(pyridin-3-yl)-1-azabicyclo[2.2.2]octane, and 2-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, a class of potent nicotinic acetylcholine receptor-ligands". The Journal of Organic Chemistry 73 (9): 3497–507. May 2008. doi:10.1021/jo800028q. PMID 18363376.
 |  |
Licensed under CC BY-SA 3.0 | Source: https://handwiki.org/wiki/Chemistry:TC-16986 views | ↧ Download this article as ZWI file
EncycloReader
is supported by the 
KSF